Abstract
We read with interest the recent report from the European Cystic Fibrosis Society Neonatal Screening Working Group that proposed parameters to evaluate outcomes of CF newborn screening (NBS) programs across European Countries and Regions [1]. This approach would allow European Countries to equitably compare key metrics to include sensitivity and specificity, timeliness, and CRMS/CFSPID detection rates. A similar set of parameters (referred to as quality indicators) has been developed in the U.S.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
